Prostratin is an unusual non-tumour promoting
phorbol ester with potential as an inductive adjuvant
therapy for
highly active antiretroviral therapy (
HAART) due to its ability to up-regulate viral expression from latent provirus. In addition,
prostratin is also able to inhibit de novo
HIV infection most probably because it induces down-regulation of
HIV receptors from the surface of target cells. In this study, we investigate the mechanisms by which
prostratin down-regulates HIV receptor and co-receptor surface expression in lymphocytic and monocytic cell lines. Our results indicate that
prostratin induces down-regulation of surface expression of CD4 and CXCR4, but not CCR5, in various cell lines. Down-regulation of CD4 and CXCR4 by
prostratin is achieved by internalization through receptor-mediated endocytosis and/or macropinocytosis, which is then followed by degradation of these molecules. Because
prostratin is a
protein kinase C (PKC) activator, we next examined the potential contribution of distinct PKC
isoforms to down-regulate CD4 and CXCR4 in response to
prostratin stimulation. Although exposure of cells to
prostratin or
phorbol-myristate-acetate (PMA) induces the translocation of several PKC
isoforms to the plasma membrane, the use of specific PKC inhibitors revealed that novel
PKCs are the main mediators of the
prostratin-induced CD4 down-regulation, whereas both conventional and novel
PKCs contribute to CXCR4 down-regulation. Altogether these results showed that
prostratin, through the activation of conventional and/or novel PKC
isoforms, rapidly reduces cell surface expression of CD4 and CXCR4, but not CCR5, by inducing their internalization and degradation.